We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




20-Minute POC Test to Diagnose STIs from Rectal and Throat Swabs

By LabMedica International staff writers
Posted on 09 Jun 2023

Every day, over a million new cases of sexually transmitted infections (STIs) are identified across the globe, making diseases such as gonorrhea and Chlamydia significant health concerns. More...

Although Chlamydia is the most frequently diagnosed STI, gonorrhea cases have also been on the rise. The World Health Organization (WHO) has reported a swift increase in multi-drug resistant gonorrhea, with almost all confirmed treatment failures linked to pharyngeal infections, impacting the throat. Traditional tests involve identifying DNA from swabs or urine samples, which require lab processing and could result in delays from several days to weeks between testing and result delivery. The extraction of DNA from rectal or pharyngeal swabs, however, presents more difficulties Now, a new testing platform technology is being optimized and validated to diagnose STIs from rectal and pharyngeal (throat) swabs.

Linear Diagnostics (Birmingham, UK), a University of Birmingham (Birmingham, UK) spinout, has received funding from the National Institute for Health and Care Research (NIHR, London, UK) to optimize and validate its LDx-CTNG platform technology. This innovative approach utilizes linear dichroism, where a beam of polarized light detects multiple targets from a single sample. The process works by detecting a shift in the plane of polarized light when a target is bound to a detector. Various molecular recognition methods can be used on the detector molecules to measure the target analytes of interest, such as using antibodies to detect antigens or oligonucleotides to capture corresponding target DNA sequences.

Linear Diagnostics' linear dichroism detection technology can identify short, rapidly synthesized DNA strands, enabling the utilization of EXPAR, an ultrafast DNA amplification method. This has drastically reduced the result delivery time compared to traditional PCR and simplified the necessary hardware due to the isothermal nature of EXPAR, which does not require complex heating and cooling cycles. The incorporation of dyes for multiplexing that absorb in the visible light spectrum has facilitated the use of affordable optical components, enabling the device to be miniaturized to a fully portable size. Moreover, the system can be operated using an internal rechargeable battery, eliminating dependence on main power sources or computer access. By pairing linear dichroism with a disposable cartridge and instrument, it is possible to perform simple point-of-care testing. A proof-of-concept study has already indicated that this technology can provide rapid and accurate diagnostic testing.

“For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately,” said Brendan Farrell, Chairman of Linear Diagnostics. “We are aiming to produce a testing platform that will meet the WHO stipulations of being easy to use with minimal training, so people can present for testing and collect their treatment in a single visit.”

Related Links:
Linear Diagnostics 
University of Birmingham 
NIHR 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Mini Vortex Mixer
Vornado
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.